Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 1838 Baiyun Avenue North, Guangzhou, 510515, China.
State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road east, Guangzhou, 510060, China.
BMC Cancer. 2023 Mar 9;23(1):221. doi: 10.1186/s12885-023-10610-1.
Large-scale genomic alterations, especially CD274/PD-L1 gene amplification, have great impact on anti-PD-1 efficacy on cancers such as Hodgkin's lymphoma. However, the prevalence of PD-L1 genetic alterations in colorectal cancer (CRC) and its correlation with the tumor immune microenvironment and clinical implications remain unknown.
PD-L1 genetic alterations were evaluated in 324 patients with newly diagnosed CRC including 160 mismatch repair-deficient (dMMR) patients and 164 mismatch repair-proficient (pMMR) patients using fluorescence in situ hybridization (FISH) method. The correlation between PD-L1 and the expression of the common immune markers was analyzed.
Totally 33 (10.2%) patients were identified with aberrant PD-L1 genetic alternations including deletion (2.2%), polysomy (4.9%), and amplification (3.1%); They had more aggressive features such as advanced stage (P = 0.02), shorter overall survival (OS) (P < 0.001) than patients with disomy. The aberrations correlated with positive lymph node (PLN) (p = 0.001), PD-L1 expression by immunohistochemistry (IHC) in tumor cells (TCs) or tumor-infiltrated immunocytes (ICs) (both p < 0.001), and pMMR (p = 0.029). When dMMR and pMMR were analyzed independently, the correlations of aberrant PD-L1 genetic alterations with PD-1 expression (p = 0.016), CD4 + T cells (p = 0.032), CD8 T + cells (p = 0.032) and CD68 + cells (p = 0.04) were only found in dMMR cohort.
The prevalence of PD-L1 genetic alterations was relatively low in CRC, but the aberrations usually correlate with aggressive nature. The correlation between PD-L1 genetic alterations and tumor immune features was only observed in dMMR CRC.
大规模基因组改变,尤其是 CD274/PD-L1 基因扩增,对霍奇金淋巴瘤等癌症的抗 PD-1 疗效有重大影响。然而,PD-L1 基因改变在结直肠癌(CRC)中的流行程度及其与肿瘤免疫微环境的相关性和临床意义尚不清楚。
采用荧光原位杂交(FISH)方法检测 324 例新诊断 CRC 患者(包括 160 例错配修复缺陷(dMMR)患者和 164 例错配修复正常(pMMR)患者)的 PD-L1 基因改变。分析 PD-L1 与常见免疫标志物表达的相关性。
共发现 33 例(10.2%)患者存在异常 PD-L1 基因改变,包括缺失(2.2%)、多倍体(4.9%)和扩增(3.1%);与二倍体患者相比,这些患者具有更具侵袭性的特征,如晚期(P=0.02)、总生存期(OS)更短(P<0.001)。异常改变与阳性淋巴结(PLN)(p=0.001)、肿瘤细胞(TCs)或肿瘤浸润免疫细胞(ICs)的 PD-L1 免疫组化(IHC)表达(均 p<0.001)和 pMMR(p=0.029)相关。当单独分析 dMMR 和 pMMR 时,异常 PD-L1 基因改变与 PD-1 表达(p=0.016)、CD4+T 细胞(p=0.032)、CD8 T+细胞(p=0.032)和 CD68+细胞(p=0.04)的相关性仅在 dMMR 队列中发现。
CRC 中 PD-L1 基因改变的发生率相对较低,但异常改变通常与侵袭性有关。PD-L1 基因改变与肿瘤免疫特征的相关性仅在 dMMR CRC 中观察到。